EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition

Lorenzo Cavina iD, Mathijs J Bouma iD, Daniel Gironés, Martin C Feiters iD

Molecules · 27.08.2024 · 29 (17) · 4047

DOI: 10.3390/molecules29174047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 27.08.2024. Verfasst von Lorenzo Cavina und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Molecules and Materials, Faculty of Science, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Antiviral Agents, Viral Nonstructural Proteins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund, European Union, EFRO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orthoflaviviruses, including zika (ZIKV), West Nile (WNV), and dengue (DENV) virus, induce severely debilitating infections and contribute significantly to the global disease burden, yet no clinically approved antiviral treatments exist. This review offers a comprehensive analysis of small-molecule drug development targeting orthoflaviviral infections, with a focus on NS2B-NS3 inhibition. We systematically examined clinical trials, preclinical efficacy studies, and modes of action for various viral replication inhibitors, emphasizing allosteric and orthosteric drugs inhibiting NS2B-NS3 protease with in vivo efficacy and in vitro-tested competitive NS2B-NS3 inhibitors with cellular efficacy. Our findings revealed that several compounds with in vivo preclinical efficacy failed to show clinical antiviral efficacy. NS3-NS4B inhibitors, such as JNJ-64281802 and EYU688, show promise, recently entering clinical trials, underscoring the importance of developing novel viral replication inhibitors targeting viral machinery. To date, the only NS2B-NS3 inhibitor that has undergone clinical trials is doxycycline, however, its mechanism of action and clinical efficacy as viral growth inhibitor require additional investigation. SYC-1307, an allosteric inhibitor, exhibits high in vivo efficacy, while temoporfin and methylene blue represent promising orthosteric non-competitive inhibitors. Compound 71, a competitive NS2B-NS3 inhibitor, emerges as a leading preclinical candidate due to its high cellular antiviral efficacy, minimal cytotoxicity, and favorable in vitro pharmacokinetic parameters. Challenges remain in developing competitive NS2B-NS3 inhibitors, including appropriate biochemical inhibition assays as well as the selectivity and conformational flexibility of the protease, complicating effective antiviral treatment design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsViral Nonstructural ProteinsHumansAnimalsProtease InhibitorsClinical Trials as TopicSerine EndopeptidasesVirus ReplicationDengue VirusZika VirusWest Nile virus

Stichwörter der Autor:innen

NS2B-NS3 inhibitorWest Nile virusdengue virusin vivo efficacyorthoflavivirusproteasezika virus

Substanzen

Antiviral AgentsViral Nonstructural ProteinsProtease InhibitorsSerine EndopeptidasesNS2B protein, flavivirus

Autor:innen und Institutionen

  • Institute for Molecules and Materials, Faculty of Science, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
  • Protinhi Therapeutics, Transistorweg 5, 6534 AT Nijmegen, The Netherlands.

ORCID-Profile: Lorenzo Cavina, Mathijs J Bouma, Martin C Feiters

Förderung

  • European Regional Development Fund
  • European Union
  • EFRO

Zitieren

APA

Cavina, L., Bouma, M. J., Gironés, D., & Feiters, M. C. (2024). Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. Molecules, 29(17), 4047. https://doi.org/10.3390/molecules29174047

Vancouver

Cavina L, Bouma MJ, Gironés D, Feiters MC. Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. Molecules. 2024;29(17):4047. doi:10.3390/molecules29174047

BibTeX
@article{Cavina2024,
  author = {Cavina, Lorenzo and Bouma, Mathijs J and Gironés, Daniel and Feiters, Martin C},
  title = {Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition},
  journal = {Molecules},
  year = {2024},
  volume = {29},
  number = {17},
  pages = {4047},
  doi = {10.3390/molecules29174047}
}
Kostenlos starten →